Tolerability profile of topical cannabidiol and palmitoylethanolamide: a compilation of single-centre randomized evaluator-blinded clinical and in vitro studies in normal skin
Controlled trialHumansTopicalWith cannabidiol
This study tested palmitoylethanolamide together with cannabidiol. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Controlled trial
- Subjects
- Healthy adult volunteers in three patch-test studies; numbers not given in the abstract. Plus a hen's egg chorioallantoic membrane test for eye irritation
- Dose used in the study
- Commercial topical products: two containing cannabidiol plus PEA, one hemp seed oil product, and four concentrations of cannabidiol alone
- Duration
- Standard patch-test schedules for irritation, sensitisation and phototoxicity
- What was measured
- Skin irritation, sensitisation and phototoxicity by evaluator-blinded patch testing; ocular irritation in vitro
What the authors reported
The study found:\n- No irritation or sensitisation from any product.\n- Mild phototoxicity from the hemp seed oil product at 48 hours.\n- The in vitro eye test placed the products with historically non-irritating products.
Limits of this study
Safety study only; no efficacy outcomes. All products from one manufacturer. Tested on normal skin, not diseased skin. Number of participants and PEA concentration not in the abstract.
Source
PubMed 33987872 · doi:10.1111/ced.14749
Entry checked against the abstract, supplied by Devlin. Sample size and PEA concentration not in the abstract on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.